Alto Neuroscience Appoints Dr. Raymond Sanchez To Board of Directors To Guide Strategic Growth In Neuropsychiatric Medicines

Alto Neuroscience, Inc., a clinical-stage biopharmaceutical company developing precision medicines for neuropsychiatric disorders, has appointed Raymond Sanchez, M.D., to its Board of Directors, effective August 12, 2025. Dr. Sanchez brings over two decades of leadership in the life sciences sector, blending deep clinical expertise with strategic insight.

Dr. Sanchez said, “As a psychiatrist by training, I’ve witnessed firsthand the lack of innovation in the field, even as it remains one of the most urgent areas of unmet medical need. I’m thrilled to join Alto at such an exciting time as the company aims to redefine the standard of care by moving beyond the outdated trial-and-error approach that has long dominated CNS drug development and clinical practice. With a robust late-stage pipeline and a strategic vision rooted in biology-driven precision medicine, I look forward to supporting Alto’s mission to deliver novel therapeutic solutions to the patients who need them most.”

Dr. Sanchez currently serves as a Senior Advisor at Bain Capital Life Sciences and sits on the boards of both Rapport Therapeutics, Inc. and several private biotech companies. He previously held the role of Chief Medical Officer at Cerevel Therapeutics, guiding the company until its 2024 acquisition by AbbVie. Before that, he spent more than a decade at Otsuka Pharmaceutical Development & Commercialization, ultimately serving as Senior Vice President of Global Clinical Development. He also concurrently served as CMO of Avanir Pharmaceuticals prior to its acquisition by Otsuka.

“We are delighted to welcome Ray to our Board of Directors as we continue advancing multiple clinical-stage precision psychiatry programs. Ray brings an impressive track record in guiding the successful development of numerous CNS therapies, and his strategic insights will be instrumental as we prepare to initiate our potentially pivotal, Phase 2b trial of ALTO-207. Ray is a tremendous addition to our board, and we believe his dedication to improving patient outcomes through innovation in psychiatry brings important contributions to our mission,” said Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto Neuroscience. 

Earlier in his career, Dr. Sanchez trained in psychiatry at the Yale School of Medicine, where he was Chief Resident, a fellow, and an instructor. He has been actively involved in advancing CNS drug development, serving as executive co-chair of the International Society for CNS Drug Development from 2017 to 2022, and contributing to organizations such as the Connecticut Mental Health Center Foundation. Dr. Sanchez earned his B.A. in psychology and M.D. from Northwestern University.